Ulcerative Colitis Adjunctive Support Protocol

Ulcerative colitis (UC) is an inflammatory bowel disease that causes chronic inflammation and ulcers in the colon and rectum. Symptoms include bloody diarrhea, abdominal pain, and urgency. UC goes through periods of flare-ups and remission. While medication is the mainstay of treatment, certain supplements may help reduce inflammation, support the gut lining, and maintain remission.

CRITICAL: UC is a serious medical condition requiring gastroenterologist care. Standard treatments include aminosalicylates, corticosteroids, immunomodulators, and biologics depending on severity. These supplements are ADJUNCTIVE—they support but don't replace medical treatment. Always inform your GI doctor about supplements.

•Curcumin (from turmeric) is one of the most promising supplements for UC. It has powerful anti-inflammatory effects, reducing the same inflammatory pathways targeted by some UC medications. Clinical trials show that curcumin added to standard therapy helps maintain remission and may help induce remission. Use a bioavailable formulation for best absorption.

•Probiotics, especially high-dose formulations like VSL#3, have strong evidence for UC. The gut microbiome is altered in UC, and restoring beneficial bacteria may reduce inflammation and support the gut barrier. VSL#3 has been studied specifically for UC and pouchitis (inflammation after surgery).

•Omega-3 Fatty Acids have anti-inflammatory effects that may help with UC, though clinical evidence is mixed. They may help reduce the inflammatory response in the colon and support mucosal healing.

•Andrographis (HMPL-004) is a traditional herb that has shown benefit in clinical trials for mild to moderate UC. It works through anti-inflammatory mechanisms similar to mesalamine.

•Vitamin D deficiency is very common in UC (both cause and effect—inflammation interferes with absorption). Low vitamin D is associated with more disease activity and higher relapse rates. Maintaining adequate levels may help reduce inflammation.

•Psyllium is a soluble fiber that ferments in the colon to produce butyrate, the preferred fuel for colonocytes (colon cells). Butyrate supports the gut barrier and has anti-inflammatory effects. Studies show psyllium may help maintain remission—comparable to mesalamine in one trial.

•Boswellia Serrata is an Ayurvedic herb with anti-inflammatory effects. It inhibits 5-lipoxygenase, reducing leukotrienes that contribute to inflammation.

•Resveratrol has antioxidant and anti-inflammatory properties. Early clinical trials suggest it may help reduce disease activity in UC.

•Aloe Vera Gel has traditional use for gut soothing. One clinical trial showed it helped reduce UC activity, though more research is needed.

Expected timeline: Curcumin: 4-8 weeks for anti-inflammatory effects. Probiotics: 2-4 weeks to shift microbiome. These supplements support long-term maintenance alongside medical therapy.

Clinical Perspective

Ulcerative colitis is characterized by continuous mucosal inflammation starting at the rectum and extending proximally (proctitis, left-sided, pancolitis). Montreal classification guides treatment. Pathophysiology: dysregulated immune response to gut microbiota in genetically susceptible individuals. Histology: crypt abscesses, goblet cell depletion, mucosal ulceration. Treatment goals: induce remission, maintain remission, achieve mucosal healing. Medical therapy: 5-ASAs, corticosteroids, thiopurines, anti-TNF, vedolizumab, ustekinumab, tofacitinib, ozanimod.

CRITICAL: UC requires gastroenterologist management. Severe flares may require hospitalization/surgery. Supplements are ADJUNCTIVE to standard therapy—not alternatives. Some supplements may interact with immunosuppressants. Long-standing UC increases colorectal cancer risk—require surveillance colonoscopy.

•Curcumin (B-grade): NF-κB inhibitor, ↓TNF-α, IL-1β, IL-6; antioxidant. RCT: curcumin + mesalamine improved remission maintenance vs placebo (PMID: 17499606). Systematic review and meta-analysis: curcumin as adjunct improves clinical and endoscopic remission (PMID: 28426088). 1-3g daily. Use bioavailable forms (piperine, phospholipid). Generally safe; may interact with anticoagulants.

•Probiotics (VSL#3/High-Dose) (B-grade): VSL#3 contains 8 strains at high concentration (450-900 billion/sachet). Restores microbiome diversity, strengthens tight junctions, reduces inflammation. Systematic review: VSL#3 effective for inducing remission and maintaining pouchitis remission (PMID: 21226722). Cochrane review: probiotics may help induce remission when added to standard therapy (PMID: 28746088). VSL#3 450-3600 billion CFU daily. E. coli Nissle 1917 also studied.

•Omega-3 Fatty Acids (C-grade): EPA/DHA are anti-inflammatory; compete with arachidonic acid. Cochrane review: omega-3s don't clearly maintain remission but may have modest benefit; heterogeneous results (PMID: 24189255). 2-4g EPA+DHA daily. May help as adjunct; monitor for fish-oil-induced diarrhea.

•Andrographis (HMPL-004) (B-grade): Contains andrographolide; anti-inflammatory (↓NF-κB, ↓COX-2). RCT: HMPL-004 comparable to mesalamine for mild-moderate UC (PMID: 22909347). 1200-1800mg daily in divided doses. Not widely available; limited to specific extracts.

•Vitamin D (B-grade): VDR expressed in gut epithelium; affects barrier function, antimicrobial peptides, immune regulation. Systematic review: vitamin D deficiency associated with disease activity; supplementation may reduce inflammation (PMID: 30179253). Target 25(OH)D 40-50 ng/mL. 2000-5000 IU daily; higher if deficient.

•Psyllium (C-grade): Soluble fiber ferments to short-chain fatty acids (butyrate = colonocyte fuel). Butyrate anti-inflammatory, supports barrier. RCT: psyllium comparable to mesalamine for maintenance (PMID: 10501660). 10-20g daily; increase gradually. May initially worsen gas/bloating; use caution in strictures.

•Boswellia Serrata (C-grade): Boswellic acids inhibit 5-lipoxygenase (reduce leukotrienes). Review: potential benefit in IBD, limited clinical data (PMID: 21226726). 300-400mg standardized extract TID. Generally well-tolerated.

•Resveratrol (C-grade): Antioxidant, ↓NF-κB, modulates gut microbiota. Clinical trial: 500mg daily reduced disease activity in UC (PMID: 28494760). Limited data. 200-500mg daily.

•Aloe Vera Gel (C-grade): Contains polysaccharides with anti-inflammatory properties. RCT: 100mL twice daily improved clinical remission vs placebo (PMID: 15043514). Small study; avoid in acute flare; diarrhea risk.

Biomarker targets: Fecal calprotectin (inflammation marker—goal <150-250 μg/g), CRP, albumin, hemoglobin (anemia common), endoscopic Mayo score (goal 0-1), histologic healing, 25(OH)D.

Protocol notes: Aminosalicylates (mesalamine) are first-line for mild-moderate UC—maintain even in remission (decreases cancer risk). Step-up therapy for inadequate response. Biologics for moderate-severe or refractory disease. Corticosteroids for acute flares only—not maintenance. Surgery (colectomy) curative but last resort. Screen for C. diff in flares. Iron supplementation for anemia (IV if intolerant or severe). Bone health monitoring (steroids, malabsorption). Colorectal cancer surveillance starting 8-10 years after diagnosis. Smoking actually protective in UC (unlike Crohn's)—but don't recommend smoking. Stress management—stress can trigger flares. Diet: avoid trigger foods (individual); low-residue in flares; fiber in remission. Consider low-FODMAP trial. Adequate calories/protein. Avoid NSAIDs (can trigger flares). Vaccine status (especially before biologics). Psychological support (IBD affects quality of life).

View All Protocols